Related Experiment Videos
Modeling toxicity and response in carboplatin-based combination chemotherapy
M J Egorin1, L M Reyno, R M Canetta
1Division of Developmental Therapeutics, University of Maryland Cancer Center, Baltimore 21201.
Seminars in Oncology
|October 1, 1994
Summary
Carboplatin and cyclophosphamide chemotherapy in advanced ovarian cancer caused more myelotoxicity than expected. Actual drug exposure varied widely, and dose intensity did not correlate with patient outcomes like time to progression or survival.
Area of Science:
- Oncology
- Pharmacology
- Clinical Medicine
Background:
- Advanced ovarian cancer (International Federation of Gynecology and Obstetrics stage III or IV) treatment often involves combination chemotherapy.
- Carboplatin pharmacokinetics and pharmacodynamics are crucial for optimizing treatment efficacy and minimizing toxicity.
Purpose of the Study:
- To evaluate pharmacokinetic/pharmacodynamic relationships of carboplatin-based combination chemotherapy in advanced ovarian cancer.
- To assess the correlation between carboplatin exposure and clinical outcomes, including time to progression and survival.
Main Methods:
- Analyzed data from 224 women with advanced ovarian cancer receiving carboplatin plus cyclophosphamide.
- Calculated carboplatin area under the plasma concentration versus time curve (AUC) and compared predicted versus observed nadir counts.
- Determined received and relative received dose intensities and defined carboplatin exposure intensity.
Main Results:
- Carboplatin combined with cyclophosphamide showed greater myelotoxicity (leukopenia, thrombocytopenia) than single-agent carboplatin.
- Platelet nadir was below predicted levels in 83% of patients.
- Received carboplatin dose intensity underestimated actual plasma drug exposure, which varied twofold within the population.
Conclusions:
- Carboplatin combination chemotherapy increases myelotoxicity in advanced ovarian cancer.
- Fixed carboplatin dosing regimens result in variable drug exposure, not accurately reflected by dose intensity.
- No consistent relationship was found between dose intensity or exposure and clinical outcomes (time to progression, survival).